/C O R R E C T I O N -- Micromet, Inc./
22 September 2009 - 12:27AM
PR Newswire (US)
In the news release, Micromet Reports Interim Data from Phase 1
Study of BiTE Antibody MT110 for the Treatment of Solid Tumors,
issued 21-Sep-2009 by Micromet, Inc. over PR Newswire, we are
advised by the company that in the second sentence, second
paragraph, "1 g" should read "1 microgram" and in the third
sentence, second paragraph, "12 g" should read "12 micrograms" as
originally issued inadvertently. The complete, corrected release
follows: BETHESDA, Md., Sept. 21 /PRNewswire-FirstCall/ --
Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company
developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases, today presented first
interim data from a phase 1 dose-escalation clinical study for BiTE
antibody MT110, the first T-cell engaging antibody for the
treatment of solid tumors. The interim data(1) were presented at
the Multidisciplinary Congress of the European Cancer Organisation
(ECCO) and 34th meeting of the European Society for Medical
Oncology (ESMO) in Berlin, Germany. MT110 is designed to direct the
patients' own T cells against cancer cells that express the
epithelial cell adhesion molecule (EpCAM). To date, 20 patients
with late-stage lung or gastrointestinal cancers have been treated
with MT110. The starting dose in this phase 1 dose escalation trial
was 1 microgram per patient per day. Results from doses up to 12
micrograms per patient per day were reported. MT110 is administered
by continuous intravenous infusion for a minimum of four weeks with
the option of additional treatment cycles until disease
progression. No maximum tolerated dose has been reached and dose
escalation is ongoing. MT110 is well tolerated with no grade 3 or 4
clinical events related to MT110 therapy observed so far. The most
frequent adverse events related to MT110 treatment were mild
pyrexia and fatigue. Laboratory analysis of all patients revealed
an early clinically asymptomatic increase of liver enzymes that
normalized after several days under continued treatment. Other
laboratory abnormalities included transient lymphopenia. No
cytokine release syndrome, pancreatitis or immune response to MT110
was observed. At the dose levels tested to date, disease
stabilization was seen in 7 of 18 evaluable patients after the
first cycle of treatment, and dose escalation continues. "We are
very encouraged by the tolerability of MT110 observed in this
heavily pre-treated population of cancer patients and look forward
to updating our results as we continue to increase the dose,"
commented Prof. Walter Fiedler from the University Hospital of
Hamburg-Eppendorf, Germany, and principal investigator of the
study. "The interim phase 1 results and activity of MT110 at the
current dose level are what we expected based on our preclinical
data," commented Christian Itin, CEO of Micromet. "We are now
looking forward to exploring the clinical activity of MT110 at
higher dose levels." MT110 is the second BiTE antibody undergoing
clinical investigation. Micromet also has ongoing trials for
blinatumomab (MT103), including a phase 2 trial for acute
lymphoblastic leukemia (ALL) and a phase 1 trial for non-Hodgkin's
lymphoma. (1) Fiedler, W. et al. (2009) Safety and pharmacology of
the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with
metastatic colorectal, gastric, or lung cancer. ECCO/ESMO Meeting,
Berlin, Abstract No. 1254 About BiTE Antibodies BiTE antibodies are
the first T cell engaging antibodies to show clinical benefit in
cancer patients, representing a new approach to cancer therapy.
While previous attempts have shown the potential for the body's
cell destroying T cells to treat cancer, these therapies have been
hampered by the cancer cells' ability to avoid recognition by T
cells. BiTE antibodies engage T cells to attack cancer cells
anywhere in the body. About Micromet, Inc. Micromet, Inc. is a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases.
Its product development pipeline includes novel antibodies
generated with its proprietary BiTE antibody platform, as well as
conventional monoclonal antibodies. Two of Micromet's BiTE
antibodies and three of its conventional antibodies are currently
in clinical trials. Micromet's preclinical product pipeline
includes several novel BiTE antibodies generated with its
proprietary BiTE antibody platform technology. Micromet's
collaboration partners include Bayer Schering Pharma, Merck Serono,
MedImmune and Nycomed. Forward-Looking Statements This release
contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. These
forward-looking statements include statements regarding the safety,
efficacy, and intended utilization of Micromet's BiTE antibody
MT110 and other product candidates, the conduct, timing and results
of future clinical trials, and expectations of the future expansion
of our product pipeline and collaborations. You are urged to
consider statements that include the words "ongoing," "may,"
"will," "believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, the risk that additional information relating to the safety,
efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or clinical trial
data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborators, including
Bayer Schering Pharma, MedImmune, Merck Serono, TRACON and Nycomed,
for the funding or conduct of further development and
commercialization activities relating to our product candidates.
These factors and others are more fully discussed in Micromet's
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30,
2009, filed with the SEC on August 6, 2009, as well as other
filings by the company with the SEC. DATASOURCE: Micromet, Inc.
CONTACT: US Media, Andrea tenBroek/Chris Stamm, +1-781-684-0770, ,
or European Media, Ludger Wess, +49(40)8816-5964, , or US
Investors, Susan Noonan, +1-212-966-3650, , or European Investors,
Ines-Regina Buth, +49(30)2363-2768, Web Site:
http://www.micromet-inc.com/
Copyright